Abstract: ObjectiveTo observe the effect of raloxifen, a selective eastrogen receptor modulator, on postmenopausal osteoporosis.MethodsSixty six patients with postmenopausal osteoporosis were randomly divided into test group and control group with 33 cases in each group. Patients in the test group were treated with raloxifen (60 mg/day) for six months, at same time; cases in the control group were treated with placebo. Before and after treatment,routine laboratory examinations, transvaginal B type ultrasonic examination, and diagnostic curettage were performed. ResultsThe bone mineral densities of lumbar vertebrae and hip were significantly higher in the test group(60.6%) than in the control group(21.2%) (P<0.01). ConclusionRaloxifen is an effective medicine to treat postmenopausal osteoporosis, and it is also safe, without side effect of stimulating endometrim, etc.

Key words: postmenopausal osteoporosis, raloxifen, bone mineral density